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Abstract
Background: Osteoporosis (OP) is a skeletal disorder characterized by reduced bone strength and predisposition to increased
risk of fracture, with consequent increased risk of morbidity and mortality. It is therefore an important public health problem.
International and Canadian associations have issued clinical guidelines for the diagnosis and treatment of OP. In this study, we
identified potential predictors of bone mineral density (BMD) testing and OP treatment, which include place of residence.
Methods: Our study was a retrospective population-based cohort study using data from the Quebec Health Insurance Board.
The studied population consisted of all individuals 65 years and older for whom a physician claimed a consultation for a low
velocity vertebral, hip, wrist, or humerus fracture in 1999 and 2000. Individuals were considered to have undergone BMD testing
if there was a claim for such a procedure within two years following a fracture. They were considered to have received an OP
treatment if there was at least one claim to Quebec's health insurance plan (RAMQ) for OP treatment within one year following
a fracture. We performed descriptive analyses and logistic regressions by gender. Predictors included age, site of fracture, social
status, comorbidity index, prior BMD testing, prior OP treatment, long-term glucocorticoid use, and physical distance to BMD
device.
Results: The cohort, 77% of which was female, consisted of 25,852 individuals with fragility fractures. BMD testing and OP
treatment rates were low and gender dependent (BMD: men 4.6%; women 13.1%; OP treatment: men 9.9%; women 29.7%).
There was an obvious regional variation, particularly in BMD testing, ranging from 0 to 16%. Logistic regressions demonstrate
that individuals living in long term care facilities received less BMD testing. Patients who had suffered from vertebral fractures,
or who had received prior OP treatment or BMD testing, regardless of gender, subsequently received more BMD testing and
OP treatments. Furthermore, increasing the distance between a patient's residence and BMD facility precluded likelihood of
BMD testing.
Conclusion: BMD testing rate was extremely low but not completely explained by reduced physical access; gender, age, social
status, prior BMD testing and OP treatment were all important predictors for future BMD testing and OP treatment.
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Background
Osteoporosis (OP) is defined as a skeletal disorder charac-
terized by reduced bone strength which predisposes a per-
son to an elevated risk of fracture [1]. This disease is an
important public health problem in societies with an ever-
increasing proportion of elderly people. It is projected
that in Canada, approximately one in four women and
one in eight men will suffer from OP during their lifetime
[2]. Fragility fracture is the main adverse consequence of
this disease.
Fragility fracture is defined by the World Health Organiza-
tion as "a fracture caused by injury that would be insufficient
to fracture a normal bone...the result of reduced compressive
and/or torsional strength of bone" [3]. Clinically, a fragility
fracture may be defined as a fracture "...that occurs as a
result of a minimal trauma, such as a fall from a standing
height or less, or no identifiable trauma" [4]. Typical fractures
in patients with osteoporosis include vertebral (spine),
proximal femur (hip), distal forearm (wrist) and proximal
humerus [4,5].
The number of fragility fractures is expected to increase
over the next 20 years in Canada; in 2041, the number of
forecast hip fractures will be 88,124, a 3-fold increase
from 1993–94 [6]. Hip and vertebral fractures are associ-
ated with a particularly high level of morbidity and mor-
tality [7-10]. One-year survival rates following a hip
fracture are reduced [11,12]. In addition, individuals who
have already sustained one fracture are at high risk for
recurrence [13-17].
Fragility fractures lead to extensive use of health care
resources and high costs of care [18-23]. Since 1998 [24],
the Osteoporosis Society of Canada recommends using
bone mineral density (BMD) measurement to confirm
diagnosis of osteoporosis [3]. Various drugs are consid-
ered effective for the treatment of osteoporosis; such as
hormonal replacement therapy and bisphosphonates
(etidronate  and  alendronate) [3,25]. During our study
period, from January 1999 to December 2000, the prov-
ince of Quebec's health insurance plan (RAMQ) was offer-
ing unrestricted coverage for osteoporosis treatments;
namely hormone replacement therapy (HRT), the
bisphosphonates etidronate and alendronate, the selective
modulator of estrogen receptors raloxifene and calcitonine
nasal spray [26].
In developed countries, awareness and use of clinical
guidelines by physicians is low. This can be partially
explained by the lack of uniformity in recommendations
[27]. In a large retrospective study, Solomon et al [28]
found that the following patient variables lowered the
probability of a physician's adherence to guidelines and
thus patients in these categories were less likely to receive
either BMD testing or OP treatment: patients aged >74
years (odds ratio [OR] = 0.49; 95% confidence interval
[CI]: 0.43 to 0.55); patients aged < 55 years (OR = 0.34;
95% CI: 0.28 – 0.42); men (OR = 0.17; 95% CI: 0.12 –
0.23); black patients (OR = 0.40; 95% CI: 0.34 – 0.47),
and patients with multiple comorbidities (OR = 0.79;
95% CI: 0.69 – 0.89). In another study, patient variables
such as female gender, glucocorticoid use, and receipt of
care from a rheumatologist all increased the likelihood of
receiving BMD [27].
The failure to adhere to OP diagnosis and treatment
guidelines results in missed opportunities for preventing
new fractures [19,21,22]. A review article examining OP
investigation, treatment and interventions following a fra-
gility fracture in different countries concluded that [29]
"Investigation of OP by bone mineral density was low: 14 to 16
studies reported investigation of less than 32% of patients."
This same study revealed that even when diagnosis of OP
was confirmed, only a fraction of patients were receiving
calcium and vitamin D supplements (8 – 62%) and
bisphosphonates (0.5 – 38%). In Canada, the proportion
of patients with fragility fractures who receive a BMD test
or a physician diagnosis of OP ranges widely from 1.7 to
50% [21]. Moreover, only 5.2 to 37.5% of patients with
fragility fractures receive pharmacotherapy (HRT,
bisphosphonates or calcitonine) for their osteoporosis
[21].
One of the factors contributing to low BMD testing in
Canada may be the low geographical accessibility to spe-
cialized BMD equipment and trained personnel. This was
well documented in two studies examining the patterns of
use of BMD in Ontario [30,31]. In the first, the age-
adjusted rate of BMD testing for the 1996–1998 time
period in 49 Ontario counties varied from 0.2 to 47.1 per
1000 women [30]. Regional rate variation analyses of
BMD performed during that same period indicated a 235-
fold variation in BMD testing across counties, these rates
being much higher in urban, south-central regions than in
rural northern Ontario. According to this study, the large
variation of access to BMD testing correlated directly with
the location of BMD devices [32]. This urban/rural differ-
ence was also observed in a survey of Ontario general
practitioners in which physicians with urban practices
reported a higher use of BMD than their rural
counterparts.
In 2001, 71 BMD devices were available in the province of
Quebec; nearly half of these were located in Montreal. To
our knowledge, regional variations in the diagnostic proc-
ess and treatment of OP have not yet been studied within
the province of Quebec.BMC Musculoskeletal Disorders 2005, 6:33 http://www.biomedcentral.com/1471-2474/6/33
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The main objectives of this study were to estimate the
BMD testing rate and OP treatment rate for people over 65
years of age who had already suffered from a fragility frac-
ture, and to examine how the location of residency is
related to BMD testing and OP treatment. We sought to
identify potential predictors of BMD testing in the two
years following a fragility fracture, as well as predictors of
OP treatment in the year following the index fracture.
Methods
Study design
We conducted a retrospective population-based cohort
study using data from the Régie de l'Assurance Maladie du
Québec  (RAMQ), the Quebec Health Insurance Board.
Quebec is the second largest Canadian province with a
population in 2001 of 7.4 million [33]. The RAMQ covers
all Quebec citizens for physician services. For prescription
drugs, the RAMQ covers people aged 65 years or more as
well as welfare recipients and people not covered by pri-
vate drug insurance.
Studied population
The studied population consisted of all individuals 65
years or older for whom a physician claimed a consulta-
tion between 1 January 1999 and 31 December 2000 for
one of the following fractures: vertebral (ICD-9 code
805), hip (ICD-9 code 820–821), wrist (ICD-9 code 814)
or proximal humerus (ICD-9 code 812). The date of the
first consultation for one of the above-mentioned frac-
tures was defined as the index date. In order to include
new cases only, we excluded all patients who had a previ-
ous vertebral, hip, wrist or humerus fracture during the 2-
year period preceding the index date. We also excluded
those who had a car accident or a work-related accident in
the week preceding the index date since those fractures are
less likely to be osteoporosis-related, and we excluded
patients for whom data on place of residence was missing.
The Northern Quebec region was excluded since it
presents unique occupational and ethnic characteristics.
Since October 1999, individuals living in a long-term care
facility have been excluded from the RAMQ drug plan as
prescription drugs are now provided free of charge by
their facility [34]. These patients were therefore also
removed from the analyses on OP treatment. Our algo-
rithm was found to have a positive predictive value of
79% in an unpublished pilot project report [35].
Data sources
Attributive and spatial data were used. Attributive data
included all patient-data available in the RAMQ database.
Data on accidents were obtained from the Quebec Car
Insurance Board and from the Quebec Occupational
Health and Security Board. Each patient was spatially ref-
erenced by his/her postal code of residence using data
from DMTI Spatial [36] and from the Quebec Ministry of
Health and Social Services [37]. The geographic coordi-
nate system (GCS) used for cartographic presentation
included at the end of the article was GCS North American
1983.
Studied variables
Using encrypted health insurance numbers, we com-
bined, at the patient level, the following RAMQ databases:
the physicians' billing database, the prescription drugs
database, the beneficiary database and the death register.
The physicians' billing database contains data on the
motive and date of consultation. The prescription drugs
database contains the name and dosage of the drug, the
duration of treatment, and the date prescriptions are
filled. The beneficiary database provided data on age, sex,
and date of death when applicable.
We assume that all BMD tests performed in the province
of Quebec are billed to the RAMQ. If there was a physician
claim for a dual-energy x-ray absorptiometry (DXA) pro-
cedure two years after the index date, the patient was con-
sidered to have undergone a BMD testing. During the
study period, DXA was the only procedure covered by the
RAMQ. We considered individuals to have received OP-
related treatment if there was at least one pharmacy claim
for a bisphosphonate (i.e. etidronate and alendronate), a
HRT (for women), raloxifene, or calcitonine within one
year after the index date. Other study variables included
sex, age of the patient at the index date, site of fracture,
type of beneficiary, comorbidity index, prior BMD testing,
prior OP treatment, long-term glucocorticoid use, and dis-
tance from residence to the nearest BMD device.
Social status was divided into the following categories:
residence in a public or subsidized private long-term care
facility; residence at home and receiving a maximum guar-
anteed income supplement or social welfare; residence at
home and receiving a partial guaranteed income supple-
ment; and living at home and not receiving any guaran-
teed income supplement. We identified an individual's
comorbidities by listing all medications other than OP
drugs taken by the individual during the year prior to the
index date [38]. Prior BMD testing was defined as a posi-
tive BMD test within the two years preceding the index
date, while prior OP treatment was defined as the billing
for at least one pharmacy claim for an OP treatment in the
year preceding the index date. Long-term use of glucocor-
ticoids was defined as glucocorticoid therapy (for at least
90 days within the 120 days before the index date) at a
dose ≥ 5 mg per day [39]. Distance from residence to the
nearest BMD device was defined as the aerial distance in
kilometers (km) from the centroid (geometric center) of
the individual's postal code to the centroid of the postal
code of the nearest BMD device. For this variable, we used
the cutpoints of 32, 64 and 105 km based on estimatedBMC Musculoskeletal Disorders 2005, 6:33 http://www.biomedcentral.com/1471-2474/6/33
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transportation times of 60, 90 and 120 minutes respec-
tively to cover these distances [40,41].
Statistical analyses
We performed descriptive analyses by gender and place of
residence and calculated age-adjusted BMD testing and
OP treatment rates. When cell counts were large enough
(>5), we used the Pearson χ2 test for comparisons between
proportions [42]; otherwise we used the Monte Carlo
exact test. For comparison between means and medians,
we used nonparametric tests (Kruskal-Wallis test, k-sam-
ple median test). We also calculated smoothed rates of
BMD testing and OP treatments, and adjusted for gender,
using the following geographically weighted regression
(GWR) approach [43]. The 30 regional rates of BMD test-
ing and the 30 regional rates of OP treatment (15 for each
sex) were modeled as a function of gender, with parame-
ters dependant on geographical coordinates of the region.
For the cartographic representation and for gender com-
parison purposes, we grouped the 15 Quebec administra-
tive regions in the same equally spaced intervals according
to the BMD age-adjusted testing rates.
Logistic regression [44] analyses were performed by gen-
der on BMD testing and OP treatment use. The potential
patient-level predictors were age category (65–69, 70–74,
75–79,  ≥ 80), site of fracture (vertebral, wrist, hip,
humerus), type of beneficiary, comorbidity index, prior
BMD, prior OP treatment, long-term glucocorticoid use,
and finally, for the BMD testing model only, distance in
kilometers from residence to the nearest BMD device. Sta-
tistical analyses were done using SAS [45], StatXact [46],
and GWR [47]. Cartographic representations were done
using ArcGIS [48].
Table 1: Characteristics of the population 65 years and older with a fragility fracture by gender
Women Men p-value
Population 65 years in 2000 554,154 387,062 -
Number of fragility fractures (per 
1000)
19,813 (36 ‰) 6039 (16 ‰) < 0.0001
Average age in years (standard 
deviation)
78.7 (7.7) 76.6 (7.6) < 0.0001
Age category in years (%) < 0.0001
65–69 2842 (14.3) 1289 (21.3)
70–74 3581 (18.1) 1326 (22.0)
75–79 4312 (21.8) 1333 (22.1)
≥80 9078 (45.8) 2091 (34.6)
Site of fragility fracture (%) < 0.0001
Vertebral 3006 (15.2) 1200 (19.9)
Wrist 3391 (17.1) 734 (12.2)
Hip 9194 (46.4) 2961 (49.0)
Humerus 4222 (21.3) 1144 (18.9)
Social status* (%) < 0.0001
Living in a LTCF 1303 (6.6) 352 (5.8)
Living at home with maximum IS 1840 (9.3) 234 (3.9)
Living at home with partial IS 8757 (44.2) 2142 (35.5)
Living at home with no IS 7913 (39.9) 3311 (54.8)
Comorbidity index – mean (quartiles) 7.2 (3, 6, 10) 6.9 (2, 6, 10) 0.0065
Prior BMD testing (%) 1572 (7.9) 100 (1.7) < 0.0001
Prior OP treatment (%) 3954 (20.0) 247 (4.1) < 0.0001
Long-term glucocorticoid use (%) 407 (2.0) 132 (2.2) 0.5310
Average distance to nearest BMD 
device
20.3 km 23.4 km < 0.0001
Median distance to nearest BMD 
device
3.0 km 3.5 km < 0.0001
BMD testing 2 years after fracture 
(%)
2594 (13.1) 281 (4.6) < 0.0001
OP treatment one year after fracture 
(%)
5889 (29.7) 596 (9.9) < 0.0001
Death 2 years after fracture (%) 4507 (22.8) 2112 (35.0) < 0.0001
* LTCF: Long-term care facility; IS: income supplementBMC Musculoskeletal Disorders 2005, 6:33 http://www.biomedcentral.com/1471-2474/6/33
Page 5 of 12
(page number not for citation purposes)
Ethical considerations
This project was approved by the Comité d'Éthique de la
Recherche sur l'humain [Ethics Board] de la Faculté de méde-
cine de l'Université de Sherbrooke and the Commission d'accès
à l'information du Québec.
Results
In 1999 and 2000, a total of 29,417 individuals aged 65
years or older consulted for a vertebral, hip, wrist or
humerus fracture. Among them, 3140 had a fragility frac-
ture within two years prior to the index date, 331 had an
accident in the week preceding the index date and 94 had
Table 2: Women 65 years and older with fragility fractures in Quebec in 1999 and 2000: mean and median distances from residence to 
the nearest BMD device, age-adjusted bone mineral density measurement rate (BMD) with corresponding BMD smoothed rates 
(BMD SR), and age-adjusted osteoporosis treatment rate (OPT) with corresponding OP treatment smoothed rates (OPT SR) by 
administrative region
Region Dist. BMD (km) mean 
(median)*
BMD (%)* BMD SR (%) OPT (%)* OPT SR (%)
Eastern Townships 18.0 (12.9) 16.1 15.8 39.9 33.2
Chaudière-Appalaches 27.1 (19.7) 14.9 14.7 35.4 34.3
Montérégie 8.8 (3.8) 14.7 14.6 31.4 30.6
Laval 3.4 (3.3) 14.6 14.5 28.8 29.8
Montreal-Center 2.0 (1.7) 14.4 14.5 26.1 29.8
Lanaudière 22.6 (12.1) 13.4 13.0 29.2 29.3
Quebec City 10.0 (2.0) 13.2 13.7 29.3 31.8
Mauricie, Central Qc 19.8 (4.5) 12.9 12.9 29.5 29.6
Laurentians 29.9 (12.8) 11.7 12.0 30.8 28.7
Outaouais 24.5 (5.4) 9.4 9.8 25.1 28.0
Saguenay-Lac-St-Jean 26.3 (13.2) 8.8 9.7 38.9 34.1
North Shore 271.4 (314.4) 4.2 3.5 30.0 30.3
Lower St. Lawrence 85.7 (74.6) 2.3 3.7 34.4 33.6
Gaspé, Magdalen Island 331.0 (322.6) 1.1 1.9 32.3 31.9
Abitibi-Témiscamingue 88.9 (92.5) 0.3 3.9 25.9 27.4
* The difference between regions is statistically significant (p < 0.0001)
Table 3: Men 65 years and older with fragility fractures in Quebec in 1999 and 2000: mean and median distances from residence to the 
nearest bone mineral density device, age-adjusted bone mineral density measurement rate (BMD) with corresponding BMD smoothed 
rates (BMD SR), and age-adjusted osteoporosis treatment rate (OPT) with corresponding OP treatment smoothed rates (OPT SR) by 
administrative region
Region Dist. BMD (km) mean 
(median)*
BMD (%)** BMD SR (%) OPT (%)* OPT SR (%)
Quebec City 10.0 (2.0) 6.1 5.4 9.0 11.3
Montérégie 8.8 (3.8) 5.7 5.3 11.7 10.6
Lanaudière 22.6 (12.1) 5.5 5.0 13.3 10.0
Eastern Townships 18.0 (12.9) 5.4 5.3 15.2 12.1
Laval 3.4 (3.3) 5.4 5.3 9.9 10.2
Montreal-Center 2.0 (1.7) 4.9 5.3 6.9 10.2
Mauricie, Central Qc 19.8 (4.5) 4.5 4.8 10.5 10.4
Chaudière-Appalaches 27.1 (19.7) 4.4 5.1 13.6 12.5
Outaouais 24.5 (5.4) 3.9 3.7 8.5 9.5
Laurentians 29.9 (12.8) 3.6 4.2 6.8 9.5
Saguenay-Lac-St-Jean 26.3 (13.2) 3.5 3.9 12.5 11.7
Gaspé, Magdalen Island 331.0 (322.6) 1.7 1.1 9.1 11.7
Abitibi-Témiscamingue 88.9 (92.5) 0.7 1.9 10.9 9.7
Lower St. Lawrence 85.7 (74.6) 0.4 1.5 14.5 12.0
North Shore 271.4 (314.4) 0.0 0.8 12.2 11.7
* The difference between regions is statistically significant (p < 0.0001)
** The difference between regions is not statistically significant (p = .0578)BMC Musculoskeletal Disorders 2005, 6:33 http://www.biomedcentral.com/1471-2474/6/33
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either incomplete data relating to the residence codes or
were living in Northern Quebec. After exclusions, the
cohort consisted of 25,852 individuals, 77% of which
were women.
Characteristics of the population are presented along gen-
der lines in Table 1. Almost all variables show statistically
significant gender differences. The 2-year incidence rates
of fragility fracture were 36 and 16 per 1000 inhabitants
for women and men respectively. A very low rate of BMD
testing at two years was found, particularly for men
(4.6%), while a statistically significant higher proportion
of men died during that same period as compared to
women. Also, OP treatment one year after the fragility
fracture was statistically lower for men (9.9%) than for
women (29.7%). A higher proportion of women than
men were recipients of the guaranteed income supple-
ment and had prior BMD testing or prior OP treatment.
Furthermore, both the mean and median distances from
home to the nearest BMD device were lower for women
than for men, and these differences were statistically sig-
nificant (p < 0.0001). On the other hand, the long-term
use of glucocorticoids failed to show any statistically sig-
nificant gender differences.
Tables 2 and 3 display age-adjusted BMD testing rates and
OP treatment rates after a fragility fracture, as well as mean
and median aerial distance between residency and BMD
device localization, for women and men, respectively.
These tables also include the smoothed rates of BMD test-
ing and OP treatment. These smoothed rates take into
account the spatial nature of the data such as the neigh-
boring regions. Figure 1 and Figure 2 display cartographic
representations of age-adjusted BMD testing rates for
women and men, respectively. There is a clear gender and
regional variation in the use of BMD testing in favor of
women and the most populated regions. For women,
BMD testing rate varies from 0.3% in Abitibi-Témis-
camingue region to 16.1% in Quebec City region, while for
men it varies from 0% in North Shore region to 6.1% in
Quebec City region. Regarding OP treatment, the regional
variation is statistically significant but is less important
than in the BMD testing rates. For women, OP treatment
varies from 25.1% in Outaouais region to 39.9% in Eastern
Townships region, whereas for men, OP treatment varies
from 6.8% in Laurentians to 15.2% in Eastern Townships
region.
Logistic regression analyses (Table 4) show that women
who had a prior BMD testing two years before the index
date (OR: 2.45), who had a vertebral fracture (OR: 2.09),
and who were exposed to OP treatment the year preceding
the index date (OR: 1.51), were all more likely to be
exposed to BMD testing. On the other hand, women aged
80 or older (OR: 0.17), women living in long-term care
facilities (OR: 0.04), women with multiple comorbid con-
ditions (OR: 0.98), and finally, women living over 105
km from the nearest BMD location (OR: 0.28), were less
likely to undergo a BMD testing. Similarly, women who,
prior to their fragility fracture, received an OP treatment
(OR: 13.6) or a long-term glucocorticoid therapy (OR:
1.45), or who were tested for BMD (OR: 2.10), as well as
those with a vertebral fracture (OR: 4.22), were more
likely to obtain OP treatment in the year following the
fracture. On the contrary, women aged 80 or older (OR:
0.60) were less likely to obtain such a treatment.
For men, logistic regression analyses (Table 5) show that
those who had a prior BMD testing two years before the
index date (OR: 5.15), those who received a long-term
glucocorticoid treatment before the fracture (OR: 2.95),
and those who had a vertebral fracture (OR: 2.77) were
more likely to be exposed to BMD testing. On the other
hand, men aged 80 or older (OR: 0.37), who lived in a
long-term care facility (OR: 0.08), and finally, men living
at more than 105 km from the nearest BMD location (OR:
0.14), were less likely to undergo a BMD testing. Likewise,
men who received an OP (OR: 14.5) or a long-term gluco-
corticoid treatment (OR: 2.44) before their fragility frac-
ture, and those who were exposed to BMD testing (OR:
3.80) prior to the fracture, were more likely to obtain an
OP treatment in the following year. Also, those with mul-
tiple comorbid conditions (OR: 1.05), those with a verte-
bral fracture (OR: 5.15), older men, and those at home
who were recipients of a partial guaranteed income sup-
plement (OR: 1.27), were more likely to receive an OP
treatment, whereas men with a wrist fracture (OR: 0.57)
were less likely to receive an OP treatment.
Discussion
As in other studies, we found a low rate of BMD testing in
high risk patients. Only 11% (13% of women and 5% of
men) of patients having suffered from a fragility fracture
were tested for osteoporosis or were tested to monitor
response to therapy in the two years following their frac-
ture. These results are comparable to the 0 to 32% [29]
and 1 to 32% [27] frequencies of testing post-fragility frac-
ture reported in large review papers. In our study, we
found that BMD testing is not completely explained by a
patient's physical access to densitometers. Gender, age
and social status also seem to influence the rate of BMD
testing.
Further, we found a moderate rate of OP treatment after a
fragility fracture. A total of 25% (30% of women and 10%
of men) of patients received an OP treatment in the year
following the fracture. This is comparable with results
from a review paper, which reported rates of bisphospho-
nate use ranging from 0.5% to 38% [29].BMC Musculoskeletal Disorders 2005, 6:33 http://www.biomedcentral.com/1471-2474/6/33
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Finally, we found regional disparities in BMD testing
according to the socio-demographic variables examined.
For instance, age-adjusted BMD testing rates found in our
study were statistically different among regions, varying
from 0.3 to 16.1% for women and from 0 to 6.1% for
men.
Hajcsar et al [49] had previously depicted gender differ-
ences in the investigation frequencies of osteoporosis.
They reported a 1-year BMD testing rate of 24% for
women and only 8.3% for men. These differences
between our results and those reported by Hajcsar et al
can be attributed to population and study design
differences.
As reported in Jaglal [32], the accessibility to BMD testing
seems to be strongly related to the use of a BMD device.
Our results however show that the distance from resi-
dence to the nearest BMD device is neither the only nor
the most important predictor of BMD testing. Younger
age, previous BMD testing, and previous OP treatment use
increased the likelihood of BMD testing, whereas social
status, such as living in a long term care facility or being
recipient of a guaranteed income supplement, decreased
Map of the regional age-adjusted rates of bone mineral density (BMD) measurement two years after a fragility fracture in  women after classification* Figure 1
Map of the regional age-adjusted rates of bone mineral density (BMD) measurement two years after a fragility 
fracture in women after classification*. * Administrative regions: 1 : Lower St. Lawrence; 2 : Saguenay-Lac-St-Jean; 3: 
Quebec City; 4: Mauricie, Central Quebec; 5: Eastern Townships; 6: Montreal Center; 7: Outaouais; 8: Abitibi-Témiscamingue; 
9: North Shore; 11: Gaspé, Magdalen Islands; 12: Chaudière-Appalaches; 13: Laval; 14: Lanaudière; 15: Laurentians; 16: 
MontérégieBMC Musculoskeletal Disorders 2005, 6:33 http://www.biomedcentral.com/1471-2474/6/33
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the likelihood of BMD testing. This last observation, not
reported in other papers, was obtained by using a unique
governmental data base that permits analysis of the
above-mentioned social variables.
In the review papers cited above, patient characteristics
were reported to influence BMD testing. In a study at two
primary care practices affiliated with an academic medical
center, Solomon et al found that some patient variables
significantly lowered the probability of a physician's
adherence to local guidelines (including BMD testing and
OP treatment). Old age and young age as opposed to mid-
dle age, male sex, black race, and having more than one
comorbid condition were associated with a decreased
likelihood of undergoing a BMD testing or receiving an
OP medication [28]. Our results are concordant with
these reported findings concerning old age and gender but
not regarding comorbidity. Comorbidity, as defined by
the number of distinct medications taken in the year pre-
ceding the fracture, was negatively correlated with BMD
testing for women, but was positively correlated with
future OP treatment. In Solomon et al [28], these two out-
comes were merged, although the authors argued that
they had observed similar results when they were exam-
Map of the regional age-adjusted rates of bone mineral density (BMD) measurement two years after a fragility fracture in men  after classification* Figure 2
Map of the regional age-adjusted rates of bone mineral density (BMD) measurement two years after a fragility 
fracture in men after classification*. * Administrative regions: 1 : Lower St. Lawrence; 2 : Saguenay-Lac-St-Jean; 3: Quebec 
City; 4: Mauricie, Central Quebec; 5: Eastern Townships; 6: Montreal Center; 7: Outaouais; 8: Abitibi-Témiscamingue; 9: North 
Shore; 11: Gaspé, Magdalen Islands; 12: Chaudière-Appalaches; 13: Laval; 14: Lanaudière; 15: Laurentians; 16: MontérégieBMC Musculoskeletal Disorders 2005, 6:33 http://www.biomedcentral.com/1471-2474/6/33
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ined separately. With regards to comorbidity, the differ-
ence between our results and those reported by Solomon
et al are likely due to differences in the methodology used
and populations studied. For instance, comorbidity was
defined differently in the two studies. Moreover, our anal-
ysis was population-based whereas Solomon et al studied
patients seen in primary care practices affiliated with an
academic medical center. Health care provided in aca-
demic centers may not be representative of the care pro-
vided to the general population.
Regarding therapy used to prevent recurrent fractures, our
results showed that positive predictors for receiving treat-
ment for both men and women were vertebral fracture,
prior BMD testing, prior OP treatment, and long-term glu-
cocorticoid use, as defined in the method section. Men
with wrist fractures and women with hip or humerus frac-
tures were less likely to be treated than individuals with
fractures at other sites. These results are concordant with
those of other studies [21,29]. The very low BMD testing
rate in patients living in long-term care facilities suggests
an important care gap in the management of OP in those
facilities.
One might argue that patients may have died before
receiving BMD testing or OP treatment. This would
explain the lower rate of care observed in long term care
facilities patients. In order to verify the stability of the
associations between predictors and outcomes, we per-
formed analyses on surviving patients during the two
Table 4: Predictors of receiving bone mineral density (BMD) measurement and predictors of osteoporosis (OP) treatment: Results 
from logistic regression models for women
BMD testing OP Treatment
Covariates Crude OR Adjusted OR (95% CI) Crude OR Adjusted OR (95% CI)
Age in years
65–69 1.00 - 1.00 -
70–74 0.71 0.79 (0.70; 0.89) *** 0.89 0.97 (0.85; 0.89 1.10)
75–79 0.42 0.52 (0.46; 0.59) *** 0.70 0.86 (0.76; 0.98) *
≥80 0.11 0.17 (0.15; 0.20) *** 0.40 0.60 (0.53; 0.67)***
Fracture
Hip 1.00 - 1.00 -
Humerus 2.14 1.42 (1.26; 1.60)*** 1.25 1.00 (0.90; 1.11)
Wrist 3.16 1.83 (1.62; 2.07) *** 1.52 1.18 (1.06; 1.32) *
Vertebral 2.17 2.09 (1.83; 2.38) *** 4.69 4.22 (3.80; 4.69) ***
Social status§
At home with no IS 1.00 - 1.00 -
At home with partial IS 0.59 0.73 (0.67; 0.81)*** 1.03 1.12 (1.03; 1.21) *
At home with max IS 0.31 0.46 (0.37; 0.56)*** 0.76 0.93 (0.81; 1.07)
Living in LTCF 0.02 0.04 (0.02; 0.10)*** - -
Comorbidity index 0.99 0.98 (0.97; 0.99) *** 1.07 1.02 (1.01; 1.03)***
Prior BMD testing 4.80 2.45 (2.16; 2.79)*** 6.19 2.10 (1.82; 2.42)***
Prior OP treatment 2.45 1.51 (1.35; 1.68)*** 16.8 13.6 (12.4; 15.0)***
Long-term glucocorticoid use 1.15 0.97 (0.71; 1.31) 3.93 1.45 (1.12; 1.89) *
Distance from BMD device
≤ 3 2  k m 1 . 0 0 ---
Between 32 and 64 km 0.68 0.75 (0.62; 0.91) *
Between 64 and 105 km 0.36 0.36 (0.25; 0.52)***
More than 105 km 0.26 0.28 (0.19; 0.40)***
* p < 0.05; ** p < 0.001; *** p < 0.0001
§ LTCF: Long-term care facility; IS: income supplementBMC Musculoskeletal Disorders 2005, 6:33 http://www.biomedcentral.com/1471-2474/6/33
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years following their fracture. These models showed simi-
lar results in predictors of BMD testing and OP treatment,
except for site of fracture, for which we observed lower
odds ratios. Exclusion of other predictors, such as prior
BMD testing and prior OP treatment showed similar
results between predictors and outcomes, except for long-
term glucocorticoid use. Indeed, since patients who had
received a long-term glucocorticoid therapy may have
been already tested and/or treated for OP, the removal of
these variables increased the associated OR.
We observed high death rates of 23% in women and 35%
in men 2 years following fragility fracture. This is a 3-fold
increase in death rates compared to those observed in the
general elderly population for the year 2001 [50]. The 1-
year death rate of the population aged 65 or older in Que-
bec in 2001 was 3.9% for women and 4.9% for men. An
increase in mortality rates following fragility fracture was
also reported in other studies [11,12].
A major strength of this study is its population based
design. Moreover, to obtain a more comprehensive model
explaining BMD use, we included a geographical distance
variable in the modeling process. The major limitation of
this study is inherent to the use of administrative data-
bases. On the one hand, we may have underestimated the
incidence of fragility fractures as some of these, such as
vertebral fractures, are notoriously under-diagnosed by
physicians [51]. We may also have overestimated inci-
dence of fragility fractures since we inferred that all frac-
Table 5: Predictors of receiving bone mineral density (BMD) measurement and predictors of osteoporosis (OP) treatment: Results 
from logistic regression models for men
BMD testing OP Treatment
Covariates Crude OR Adjusted OR (95% CI) Crude OR Adjusted OR (95% CI)
Age in years
65–69 1.00 - 1.00 -
70–74 0.97 0.96 (0.69; 1.33) 1.42 1.46 (1.06; 2.01) *
75–79 0.86 0.86 (0.61; 1.20) 1.75 1.64 (1.20; 2.25) *
≥80 0.34 0.37 (0.25; 0.54) *** 1.44 1.54 (1.14; 2.08)*
Fracture
Hip 1.00 - 1.00 -
Humerus 1.40 1.09 (0.75; 1.58) 0.87 0.84 (0.60; 1.17)
Wrist 1.34 1.01 (0.65; 1.57) 0.50 0.57 (0.35; 0.91) *
Vertebral 3.53 2.77 (2.06; 3.72)*** 5.49 5.15 (4.13; 6.42) ***
Social status§
At home with no IS 1.00 - 1.00 -
At home with partial IS 0.79 0.81 (0.62; 1.06) 1.33 1.27 (1.04; 1.56) *
At home with max IS 0.79 0.77 (0.40; 1.51) 1.10 1.26 (0.77; 2.07)
Living in LTCF 0.05 0.08 (0.01; 0.57)* - -
Comorbidity index 1.03 1.00 (0.98; 1.02) 1.09 1.05 (1.04; 1.07)***
Prior BMD testing 9.71 5.15 (3.00; 8.85)*** 15.8 3.80 (2.19; 6.58)***
Prior OP treatment 3.45 1.36 (0.83; 2.23) 26.1 14.5 (10.4; 20.1)***
Long-term glucocorticoid use 5.16 2.95 (1.75; 4.97) 7.82 2.44 (1.54; 3.86) **
Distance from BMD device
≤ 32 km 1 . 0 0 ---
Between 32 and 64 km 1.03 0.99 (0.64; 1.52)
Between 64 and 105 km 0.61 0.65 (0.30; 1.41)
More than 105 km 0.14 0.14 (0.03; 0.55)*
* p < 0.05; ** p < 0.001; *** p < 0.0001
§ LTCF: Long-term care facility; IS: income supplementBMC Musculoskeletal Disorders 2005, 6:33 http://www.biomedcentral.com/1471-2474/6/33
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tures not associated with a high velocity trauma were
fragility fractures. However, in an unpublished pilot
study, we found a positive predictive value of 79% for fra-
gility fracture diagnosis based on this definition [35]. One
of the limitations regarding the use of the guaranteed
income supplement as a social status indicator includes a
possible under-estimation of the number of beneficiaries
in this category, as nearly 31% of individuals in Canada
who are admissible for a guaranteed income supplement
do not benefit from it [52]. Furthermore, as we have
excluded fragility fractures within the 2 years prior to the
index date we may have excluded at risk patients. Unfor-
tunately, we are limited by the fact that data before the
year 1997 are unavailable. It is well known that physician
characteristics may affect the incidence of BMD testing
[27,28]. Although we acknowledge the importance of
studying physician characteristics in the modeling proc-
ess, we were unable to retrieve such data for technical
reasons.
Conclusion
We found in our study that the use of BMD testing two
years after a fragility fracture was extremely low despite
strong clinical guideline recommendations. This finding
was not completely explained by geographical distances
depriving patients' physical access to densitometers. Previ-
ous medical conditions including comorbidities, use of
glucocorticoid or OP therapy, as well as fracture site were
other important predictors of BMD testing and OP treat-
ment. We found that other socio-demographic factors,
such as gender, age and social status, were also important
predictors of care provision in patients having suffered
from fragility fracture.
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